

Highlights of This Issue 2475

REVIEW

- 2477** **Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance**
Enrique Rozengurt, Heloisa P. Soares, and James Sinnet-Smith

SMALL MOLECULE THERAPEUTICS

- 2489** **Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma**
Diana Cirstea, Loredana Santo, Teru Hideshima, Homare Eda, Yuko Mishima, Neeharika Nemani, Anuj Mahindra, Andrew Yee, Gullu Gorgun, Yiguo Hu, Hiroto Ohguchi, Rikio Suzuki, Francesca Cottini, Sylvie M. Guichard, Kenneth C. Anderson, and Noopur Rajee
- 2501** **Dual Targeting of Hypoxia and Homologous Recombination Repair Dysfunction in Triple-Negative Breast Cancer**
Francis W. Hunter, Huai-Ling Hsu, Jiechuang Su, Susan M. Pullen, William R. Wilson, and Jingli Wang
- 2515** **Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer**
Mary Ellen Molloy, Bethany E. Perez White, Teshome Gherezghiher, Bradley T. Michalsen, Rui Xiong, Hitisha Patel, Huiping Zhao, Philipp Y. Maximov, V. Craig Jordan, Gregory R.J. Thatcher, and Debra A. Tonetti
- 2527** **Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent *In Vitro* Antitumor Activity in Gastric Cancer Cell Lines with *FGFR2* Amplification**
Seung Tae Kim, Hye-Lim Jang, Su Jin Lee, Jeeyun Lee, Yoon-La Choi, Kyoung-Mee Kim, Jeonghee Cho, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Masakazu Yashiro, Won Ki Kang, and Joon Oh Park
- 2537** **Small Molecule BMH-Compounds That Inhibit RNA Polymerase I and Cause Nucleolar Stress**
Karita Peltonen, Laureen Colis, Hester Liu, Sari Jäämaa, Zhewei Zhang, Taija af Hällström, Henna M. Moore, Paul Sirajuddin, and Marikki Laiho

- 2547** **The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor**
Yoshito Nakanishi, Nukinori Akiyama, Toshiyuki Tsukaguchi, Toshihiko Fujii, Kiyooki Sakata, Hitoshi Sase, Takehito Isobe, Kenji Morikami, Hidetoshi Shindoh, Toshiyuki Mio, Hirosato Ebiike, Naoki Taka, Yuko Aoki, and Nobuya Ishii
- 2559** **Monensin Inhibits Epidermal Growth Factor Receptor Trafficking and Activation: Synergistic Cytotoxicity in Combination with EGFR Inhibitors**
Khalil Dayekh, Stephanie Johnson-Obaseki, Martin Corsten, Patrick J. Villeneuve, Harmanjatinder S. Sekhon, Johanne I. Weberpals, and Jim Dimitroulakos
- 2572** **Targeted Silencing of MLL5 β Inhibits Tumor Growth and Promotes Gamma-Irradiation Sensitization in HPV16/18-Associated Cervical Cancers**
Dawn Sijin Nin, Chow Wenn Yew, Sun Kuie Tay, and Lih-Wen Deng
- 2583** **Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin-Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma**
Vianey Gonzalez-Villasana, Cristian Rodriguez-Aguayo, Thiruvengadam Arumugam, Zobeida Cruz-Monserrate, Enrique Fuentes-Mattei, Defeng Deng, Rosa F. Hwang, Huamin Wang, Cristina Ivan, Raul Joshua Garza, Evan Cohen, Hui Gao, Guillermo N. Armaiz-Pena, Paloma del C. Monroig-Bosque, Bincy Philip, Mohammed H. Rashed, Burcu Aslan, Mumin Alper Erdogan, Yolanda Gutierrez-Puente, Bulent Ozpolat, James M. Reuben, Anil K. Sood, Craig Logsdon, and Gabriel Lopez-Berestein
- 2595** **Development of Targeted Near-Infrared Imaging Agents for Prostate Cancer**
Xinning Wang, Steve S. Huang, Warren D.W. Heston, Hong Guo, Bing-Cheng Wang, and James P. Basilion

Table of Contents

LARGE MOLECULE THERAPEUTICS

- 2607** **Anti-MET ImmunoPET for Non-Small Cell Lung Cancer Using Novel Fully Human Antibody Fragments**
Keyu Li, Richard Tavaré, Kirstin A. Zettlitz, Shannon M. Mumenthaler, Parag Mallick, Yu Zhou, James D. Marks, and Anna M. Wu
- 2618** **Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform**
Wim Dokter, Ruud Ubink, Miranda van der Lee, Monique van der Vleuten, Tanja van Achterberg, Danielle Jacobs, Eline Loosveld, Diels van den Dobbels, David Egging, Ellen Mattaar, Patrick Groothuis, Patrick Beusker, Ruud Coumans, Ronald Elgersma, Wiro Menge, John Joosten, Henri Spijker, Tijn Huijbregts, Vincent de Groot, Michel Eppink, Guy de Roo, Gijs Verheijden, and Marco Timmers
- 2630** **An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models**
Suzie J. Scales, Nidhi Gupta, Glenn Pacheco, Ron Firestein, Dorothy M. French, Hartmut Koeppen, Linda Rangell, Vivian Barry-Hamilton, Elizabeth Luis, Josefa Chuh, Yin Zhang, Gladys S. Ingle, Aimee Fourie-O'Donohue, Katherine R. Kozak, Sarajane Ross, Mark S. Dennis, and Susan D. Spencer
- 2641** **A Chemically Defined Trifunctional Antibody-Cytokine-Drug Conjugate with Potent Antitumor Activity**
Thomas List, Giulio Casi, and Dario Neri
- 2653** **Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers**
Christine Alewine, Laiman Xiang, Takao Yamori, Gerhard Niederfellner, Klaus Bosslet, and Ira Pastan
- 2662** **MEDI-573, Alone or in Combination with Mammalian Target of Rapamycin Inhibitors, Targets the Insulin-like Growth Factor Pathway in Sarcomas**
Haihong Zhong, Christine Fazenbaker, Shannon Breen, Cui Chen, Jiaqi Huang, Christopher Morehouse, Yihong Yao, and Robert E. Hollingsworth

- 2674** **Therapeutic Targeting of Angiogenesis with a Recombinant CTT Peptide-Endostatin Mimic-Kringle 5 Protein**
Houbin Wang, Zhigang Yang, and Jun Gu
- 2688** **Development of Human Serine Protease-Based Therapeutics Targeting Fn14 and Identification of Fn14 as a New Target Overexpressed in TNBC**
Hong Zhou, Khalid A. Mohamedali, Ana Maria Gonzalez-Angulo, Yu Cao, Mary Migliorini, Lawrence H. Cheung, Janine LoBello, Xiudong Lei, Yuan Qi, Walter N. Hittelman, Jeffrey A. Winkles, Nhan L. Tran, and Michael G. Rosenblum

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

- 2706** **Longitudinal Time-Dependent Effects of Irradiation on Multidrug Resistance in a Non-Small Lung Cancer Cell Line**
Yumiko Kono, Keita Utsunomiya, Shohei Kanno, and Noboru Tanigawa
- 2713** **SNAI2 Modulates Colorectal Cancer 5-Fluorouracil Sensitivity through miR145 Repression**
Victoria J. Findlay, Cindy Wang, Lourdes M. Nogueira, Katie Hurst, Daniel Quirk, Stephen P. Ethier, Kevin F. Staveley O'Carroll, Dennis K. Watson, and E. Ramsay Camp
- 2727** **Tissue Penetration and Activity of Camptothecins in Solid Tumor Xenografts**
Alastair H. Kyle, Jennifer H.E. Baker, Maria-Jose Gandolfo, Stefan A. Reinsberg, and Andrew I. Minchinton

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

- 2738** **A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma**
Tuhina Mazumdar, Lauren A. Byers, Patrick Kwok Shing Ng, Gordon B. Mills, Shaohua Peng, Lixia Diao, You-Hong Fan, Katherine Stemke-Hale, John V. Heymach, Jeffrey N. Myers, Bonnie S. Glisson, and Faye M. Johnson

Table of Contents

MODELS AND TECHNOLOGIES

- 2751 Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics**
Manuela Gridling, Scott B. Ficarro, Florian P. Breitwieser, Lanxi Song, Katja Parapatics, Jacques Colinge, Eric B. Haura, Jarrod A. Marto, Giulio Superti-Furga, Keiryn L. Bennett, and Uwe Rix

LETTERS TO THE EDITOR

- 2763 PDT with a Glucose-Conjugated Chlorin for GIST—Letter**
Mark Linch and Andrew J. Hayes

- 2764 PDT with a Glucose-Conjugated Chlorin for GIST—Response**
Hiromi Kataoka and Mamoru Tanaka

CORRECTION


- 2765 Correction: The Aurora Kinase A Inhibitor MLN8237 Enhances Cisplatin-Induced Cell Death in Esophageal Adenocarcinoma Cells**

 AC icon indicates Author Choice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

Interrelation between vasculature, blood flow, proliferation, and hypoxia is shown in an HCT116 tumor xenograft 24 hours following irinotecan treatment. Irinotecan initially halts proliferation throughout the tissue but by 24 hours the S-phase fraction returns to near-control levels. The image was produced using multiplexed immunohistochemistry to illustrate the effects of drugs in the context of the tumor microenvironment. Greyscale images of the individual staining patterns were coregistered to produce the composite image shown here. HCT116 xenografts exhibit a corded architecture, where sheaths of tumor cells can be seen to surround individual vessels. Cells can survive to ~150 μ m away from the blood vessels but become increasingly oxygen-deprived and eventually necrose. For details, see the article by Kyle and colleagues on page 2727.



Molecular Cancer Therapeutics

13 (11)

Mol Cancer Ther 2014;13:2475-2766.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/13/11>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/13/11>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.